Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomised, Placebo-controlled, Event-driven Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death

NCT06677060 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06677060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06677060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomised, Placebo-controlled, Event-driven Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
March 14, 2025
Completion date
December 17, 2029
Enrollment
11,300 (estimated)
Sites
957

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure